Galapagos NV Logo

Galapagos NV

A biotechnology company focused on a rapid, decentralized cell therapy platform.

GLPG | BR

Overview

Corporate Details

ISIN(s):
BE0003818359
LEI:
549300QKJ78IY0IOV655
Country:
Belgium
Address:
Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, 2800 Mechelen

Description

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 07:30
GALAPAGOS_NV_Corp_Structure_TD_14.11.2025.pdf
German 151.3 KB
2025-11-26 07:30
GALAPAGOS_NV_Corp_Structure_TD_12.11.2025.pdf
German 151.9 KB
2025-11-26 07:30
GALAPAGOS NV Form TD 14.11.2025_Revised Part I.pdf
English 956.3 KB
2025-11-26 07:30
GALAPAGOS NV Form TD 12.11.2025_Part I_Revision2.pdf
English 956.0 KB
2025-11-26 07:30
Galapagos Receives Transparency Notifications from Bank of America .pdf
English 243.9 KB
2025-11-26 07:30
Galapagos ontvangt transparantieverklaringen van Bank of America .pdf
Dutch 283.4 KB
2025-11-05 22:01
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Upda…
English 465.4 KB
2025-11-05 22:01
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 20…
Dutch 593.4 KB
2025-10-21 07:30
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the…
English 274.0 KB
2025-10-21 07:30
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onde…
Dutch 288.2 KB
2025-08-08 07:36
Galapagos Creates New Subscription Right Plan
Dutch 203.1 KB
2025-08-08 07:36
Galapagos Creates New Subscription Right Plan
English 201.6 KB
2025-08-07 00:00
Galapagos_PR_07082025_ENG.pdf
English 208.3 KB
2025-08-07 00:00
Galapagos_PR_07082025_NL.pdf
Dutch 215.6 KB
2025-08-07 00:00
1. Subscription Right Plan 2025 (B)_Board Report_7_180-7_191_ENG_FINAL_Website(…
English 262.4 KB

Automate Your Workflow. Get a real-time feed of all Galapagos NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Galapagos NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Galapagos NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-22 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 58,375 1,681,760.40 USD
2025-05-22 EcoR1 Capital Fund, L.P. Close relation Buy 3,898 112,299.82 USD
2025-05-20 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 14,321 412,553.64 USD
2025-05-20 EcoR1 Capital Fund, L.P. Close relation Buy 956 27,540.07 USD
2025-05-19 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 9,376 261,151.60 USD
2025-05-19 EcoR1 Capital Fund, L.P. Close relation Buy 626 17,436.10 USD
2025-05-16 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 39,112 1,077,934.54 USD
2025-05-16 EcoR1 Capital Fund, L.P. Close relation Buy 2,612 71,987.24 USD
2025-05-15 EcoR1 Capital Fund Qualified, L.P. Close relation Buy 187,480 5,015,090.00 USD
2025-05-15 EcoR1 Capital Fund, L.P. Close relation Buy 12,520 334,910.00 USD

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.